ST. LOUIS, May 15, 2024 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today it was named one of the Top 50 Companies for Diversity by Fair360 (formerly DiversityInc) for the fourth consecutive year. Centene ranked No. 26 on this year's list, up 11 spots from No. 37. The list assesses and ranks the nation's largest employers on comprehensive, data-driven diversity and inclusion metrics across six key areas: leadership accountability, human capital metrics, talent programs, workforce practices, supplier fairness and philanthropy.
"We know that we best serve our diverse customers when our workforce reflects and is part of the communities we serve," said Centene Chief Executive Officer, Sarah M. London. "I'm so proud that Centene is once again one of Fair360's Top 50 Companies for Diversity, because it shows our continued dedication to cultivating an employee population that deeply understands the needs and experiences of our members."
Centene was also included in three of Fair360's specialty ranking lists: No. 7 for Top Companies for Talent Acquisition for Women of Color, No. 9 for Top Companies for Executive Women and No. 18 for Top Companies for People with Disabilities.
Centene recently released its Sustainability & DEI Report: Healthy Futures, Diverse Horizons, which underscores the company's continued efforts to integrate diversity, equity and inclusion (DEI) in order to better deliver high-quality, culturally sensitive healthcare to the more than 28 million members the company serves nationwide.
Today's announcement adds to several recent awards acknowledging Centene's commitment to DEI. Most recently, Centene was recognized by Forbes magazine as one of "America's Best Employers for Diversity 2024" and one of "America's Greatest Workplaces for Diversity 2024" by Newsweek, both for the second consecutive year. Centene was also listed on the 2023 Bloomberg Gender-Equality Index for the fourth year and named one of 2024's World's Most Admired Companies for the sixth consecutive year by Fortune.
For a full list of Centene's corporate awards and recognitions, visit https://www.centene.com/who-we-are/accreditations-awards.html.
About Centene Corporation
Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. The Company also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and value creation as well as the development of its people, systems and capabilities so that it can better serve its members, providers, local communities and government partners.
Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, http://investors.centene.com.
Last Trade: | US$33.26 |
Daily Change: | -0.82 -2.41 |
Daily Volume: | 14,543,229 |
Market Cap: | US$16.330B |
July 29, 2025 July 25, 2025 April 25, 2025 February 24, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load